Abstract
Trimebutine has been used for treatment of both hypermotility and hypomotility disorders of the gastrointestinal (GI) tract, such as irritable bowel syndrome. In this issue, Tan et al. (2011) examined the concentration-dependent dual effects of trimebutine on colonic motility in guinea pig. The authors suggested that trimebutine attenuated colonic motility mainly through the inhibition of L-type Ca2+ channels at higher concentrations, whereas, at lower concentrations, it depolarized membrane potentials by reducing BKca currents, resulting in the enhancement of the muscle contractions. Trimebutine might be a plausible modulator of GI motility, which gives an insight in developing new prokinetic agents. Further studies to elucidate the effects of trimebutine on the interstitial cells of Cajal, the pacemaker in GI muscles would promote the therapeutic benefits as a GI modulator.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Delvaux, M. and Wingate, D., Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J. Int. Med. Res., 25, 225–246 (1997).
Farrugia, G., Ca2+ handling in human interstitial cells of Cajal. Gastroenterology, 132, 2057–2059 (2007).
Fioramonti, J. and Bueno, L., Centrally acting agents and visceral sensitivity. Gut, 51Suppl 1, i91–i95 (2002).
Hwang, S. J., Blair, P. J., Britton, F. C., O’Driscoll, K. E., Hennig, G., Bayguinov, Y. R., Rock, J. R., Harfe, B. D., Sanders, K. M., and Ward, S. M., Expression of anoctamin1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. J. Physiol., 587, 4887–4904 (2009).
Kim, B. J., So, I., and Kim, K. W., The relationship of TRP channels to the pacemaker activity of interstitial cells of Cajal in the gastrointestinal tract. J. Smooth Muscle Res., 42, 1–7 (2006).
Long, Y., Liu, Y., Tong, J., Qian, W., and Hou, X., Effectiveness of trimebutine maleate on modulating intestinal hypercontractility in a mouse model of postinfectious irritable bowel syndrome. Eur. J. Pharmacol., 636, 159–165 (2010).
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., and Spiller, R. C., Functional bowel disorders. Gastroenterology, 130, 1480–1491 (2006).
Mearin, F., Badía, X., Balboa, A., Baró, E., Caldwell, E., Cucala, M., Díaz-Rubio, M., Fueyo, A., Ponce, J., Roset, M., and Talley, N. J., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand. J. Gastroenterol., 36, 1155–1161 (2001).
Morisawa, T., Hasegawa, J., Tanabe, K., Watanabe, A., Kitano, M., and Kishimoto, Y., Effects of trimebutine maleate on delayed rectifier K+ currents in guinea-pig ventricular myocytes. J. Pharm. Pharmacol., 52, 403–408 (2000).
Nagasaki, M., Kobayashi, T., and Tamaki, H., Effects of trimebutine on cytosolic Ca2+ and force transitions in intestinal smooth muscle. Eur. J. Pharmacol., 195, 317–321 (1991).
Nagasaki, M., Komori, S., and Ohashi, H., Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells. Br. J. Pharmacol., 110, 399–403 (1993a).
Nagasaki, M., Komori, S., Tamaki, H., and Ohashi, H., Effect of trimebutine on K+ current in rabbit ileal smooth muscle cells. Eur. J. Pharmacol., 235, 197–203 (1993b).
Pasricha, P. J., Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology, 132, 2287–2290 (2007).
Roman, F. J., Lanet, S., Hamon, J., Brunelle, G., Maurin, A., Champeroux, P., Richard, S., Alessandri, N., and Gola, M., Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. J. Pharmacol. Exp. Ther., 289, 1391–1397 (1999).
Sanders, K. M., Interstitial cells of Cajal at the clinical and scientific interface. J. Physiol., 576, 683–687 (2006).
Simrén, M., Brazier, J., Coremans, G., Dapoigny, M., Müller-Lissner, S. A., Pace, F., Smout, A. J., Stockbrügger, R. W., Vatn, M. H., and Whorwell, P. J., Quality of life and illness costs in irritable bowel syndrome. Digestion, 69, 254–261 (2004).
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., and Whorwell, P., Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut, 56, 1770–1798 (2007).
Takenaga, H., Magaribuchi, T., and Tamaki, H., Effects of trimebutine maleate (TM-906) on the spontaneous contraction of isolated duodenum and ileum in both guinea pigs and rabbits. Jpn. J. Pharmacol., 40, 13–20 (1986).
Tan, W., Zhang, H., Luo, H.-S., and Xia, H., Effects of trimebutine maleate on colonic motility through Ca2+-activated K+ channels and L-type Ca2+ channels. Arch. Pharm. Res., 34, 979–985 (2011).
Won, K. J., Sanders, K. M., and Ward, S. M., Interstitial cells of Cajal mediate mechanosensitive responses in the stomach. Proc. Natl. Acad. Sci. U. S. A., 102, 14913–14918 (2005).
Zhu, M. H., Kim, T. W., Ro, S., Yan, W., Ward, S. M., Koh, S. D., and Sanders, K. M., A Ca2+-activated Cl− conductance in interstitial cells of Cajal linked to slow wave currents and pacemaker activity. J. Physiol., 587, 4905–4918 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, HT., Kim, B.J. Trimebutine as a modulator of gastrointestinal motility. Arch. Pharm. Res. 34, 861–864 (2011). https://doi.org/10.1007/s12272-011-0600-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0600-7